Search results for "HODGkin lymphoma"

showing 10 items of 62 documents

LDH uzticamība ne-Hodžkina limfomas ārstēšanas terapijas efektivitātēs izvērtēšanai

2022

Saikne starp laktātdehidrogenāzi un ne-Hodžkina limfomu ir pierādīta, taču laktātdehidrogenāzes loma ir palikusi tikai prognostiska. Šajā pētījumā mēs nolēmām izpētīt, vai laktāta dehidrogenāze varētu aizstāt radioloģiskus izmeklējumus, piemēram, datortomogrāfiju un pozitronu emisijas tomogrāfiju,lai izvērtētu ne-Hodžkina limfomas ārstēšanas efektivitāti. Tika veikts retrospektīvs kvantitatīvs pētījums. Tika atlasīti 39 pacienti no Paula Stradiņa Klīniskās universitātes slimnīcas. Tika analizēti pacienta laboratoriskie un radioloģiskie izmeklējumi, mēs analizējām datus, izmantojot SPSS. Pacientiem diagnozes noteikšanas brīdī bija visaugstākais LDH līmenis, un ārstēšanas laikā LDH līmenis sa…

LymphomaNon-Hodgkin LymphomaLactate dehydrogenasePET scanMedicīnaCancer
researchProduct

Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate

2018

Abstract Background Acquired angioedema due to C1-inhibitor (C1-INH) deficiency (AAE-C1-INH) is a serious condition that may result in life-threatening asphyxiation due to laryngeal edema. It is associated with malignant B-cell lymphoma and other disorders. The purpose of this study was to describe the characteristics and associated disorders of patients with AAE-C1-INH and assess the efficacy of plasma-derived C1-INH concentrate (pdC1-INH) in the treatment of AAE-C1-INH. Forty-four patients with AAE-C1-INH from the Angioedema Outpatient Service of Mainz were assessed for associated disorders. In 32 of these patients, the duration of swelling attacks was measured before and after treatment …

Male0301 basic medicinelcsh:Medicine030105 genetics & heredityGastroenterologyAcquired angioedemaC1-inhibitor0302 clinical medicineGermanyImmunology and Allergyheterocyclic compoundsPharmacology (medical)Genetics (clinical)Non-Hodgkin lymphomaAged 80 and overC1-inhibitor deficiencybiologyGeneral MedicineMiddle Agedrespiratory systemTreatment OutcomeC1-inhibitor concentrate C1-inhibitor antibodiesFemalemedicine.symptomComplement C1 Inhibitor ProteinAdultmedicine.medical_specialtyC1 inhibitor deficiencyImmunologyMalignancyLaryngeal Edema03 medical and health sciencesInternal medicinemedicineHumansAngioedemaAgedRetrospective StudiesAngioedemabusiness.industryResearchlcsh:RAngioedemas HereditaryAutoantibodybiochemical phenomena metabolism and nutritionbacterial infections and mycosesmedicine.diseaserespiratory tract diseasesLymphomabiology.proteinbusiness030217 neurology & neurosurgeryMonoclonal gammopathy of undetermined significanceOrphanet Journal of Rare Diseases
researchProduct

Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary?

2016

Abstract The purpose of the study was to determine if abdomen/pelvis computed tomography (CT) can be safety omitted in the initial staging of a subgroup of children affected by Hodgkin Lymphoma (HL). Every participating center of A.I.E.O.P (Associazione Italiana di Ematologia ed Oncologia Pediatrica) sent local staging reports of 18F‐fluorodeoxyglucose positron emission tomography (PET) and abdominal ultrasound (US) along with digital images of staging abdomen/pelvis CT to the investigation center where the CT scans were evaluated by an experienced pediatric radiologist. The local radiologist who performed the US was unaware of local CT and PET reports (both carried out after US), and the r…

MaleCancer Researchmedicine.medical_specialtyPediatric RadiologistComputed tomographyMultimodal ImagingSensitivity and SpecificityPelvis03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyAbdomenmedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinePelvisNeoplasm StagingOriginal Researchmedicine.diagnostic_testHodgkin Lymphomabusiness.industryAbdomen+PelvisClinical Cancer ResearchHodgkin DiseaseChildhoodPETmedicine.anatomical_structureOncologyPositron emission tomographyPositron-Emission Tomography030220 oncology & carcinogenesisHodgkin lymphomaAbdomenFemaleLymph NodesRadiologyTomography X-Ray ComputedbusinessCancer Medicine
researchProduct

Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience

2019

Many studies have reported a more favorable outcome in younger patients with Hodgkin lymphoma (HL). The aims of this study were to find an appropriate age cutoff able to identify low-risk children and to describe the natural history of 135 very young patients affected by classic HL (cHL). The best age cutoff was identified at 7 years of age. EFS (p = .0451) and PFS (p = .00921) were significantly better in the group of younger patients. The OS rate at 10 years was 97.0% in the younger group and 92.5% in the older one (p = .0448). However, age was not found to be an independent prognostic factor in multivariate analysis and the better prognosis in younger patients seems to be related to more…

MaleCancer Researchmedicine.medical_specialtyPrognostic factorMultivariate analysisAdolescent03 medical and health sciences0302 clinical medicineInternal medicineOutcome Assessment Health CaremedicineCutoffHumansPublic Health SurveillanceFavorable outcomeAge of OnsetChildchemotherapeutic approachesbusiness.industryAge FactorsDisease ManagementInfantHematologyPrognosisHodgkin DiseaseSurvival AnalysisNatural historypediatricOncologyItalyROC CurveSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisChild PreschoolLymphoma and Hodgkin diseaseHodgkin lymphomaDisease characteristicsFemalebusiness030215 immunology
researchProduct

Tumor necrosis factor (TNF) and lymphotoxin-a (LTA) polymorphisms and risk of non-hodgkin lymphoma in the interLymph consortium

2010

In an International Lymphoma Epidemiology Consortium pooled analysis, polymorphisms in 2 immune-system-related genes, tumor necrosis factor (TNF) and interleukin-10 (IL10), were associated with non-Hodgkin lymphoma (NHL) risk. Here, 8,847 participants were added to previous data (patients diagnosed from 1989 to 2005 in 14 case-control studies; 7,999 cases, 8,452 controls) for testing of polymorphisms in the TNF -308G>A (rs1800629), lymphotoxin-alpha (LTA) 252A>G (rs909253), IL10 -3575T>A (rs1800890, rs1800896), and nucleotide-binding oligomerization domain containing 2 (NOD2) 3020insC (rs2066847) genes. Odds ratios were estimated for non-Hispanic whites and several ethnic subgroups using 2-…

MaleEpidemiologyTNFGastroenterology0302 clinical medicineRisk Factorsimmune system diseaseshemic and lymphatic diseasesAged 80 and over0303 health scienceseducation.field_of_studyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMiddle Aged3. Good healthInterleukin-10EuropeLTA030220 oncology & carcinogenesisFemaleLymphotoxin alphaAdultmedicine.medical_specialtyCanadaAdolescentTumor necrosis factorMeta- and Pooled AnalysesPopulationPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Predisposition to Diseaseeducation030304 developmental biologyAgedMycosis fungoidesbusiness.industryTumor Necrosis Factor-alphaAustraliaInternational AgenciesInterLymph ConsortiumOdds ratiomedicine.diseaseUnited StatesNon-Hodgkin's lymphomaLymphomaCase-Control StudiesImmunologyMantle cell lymphomalymphotoxin-alphabusinessDiffuse large B-cell lymphoma
researchProduct

MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma

2003

The MALT1 gene was identified through its involvement in t(11;18)(q21;q21), seen in 30% of cases of mucosa-associated lymphoid tissue (MALT) lymphoma. Here, we show that deregulated MALT1 expression may occur in B-cell non-Hodgkin lymphoma (B-NHL) of various histologic subtypes either through translocation to the immunoglobulin heavy chain (IGH) locus or by genomic amplification. First, 2 cases, one case of MALT lymphoma and another of aggressive marginal zone lymphoma (MZL) with t(14;18)(q32;q21), cytogenetically identical to the translocation involving BCL2, were shown by fluorescence in situ hybridization (FISH) to involve MALT1, which lies about 5 Mb centromeric of BCL2. Molecular cloni…

MaleLymphoma B-CellImmunologyBiologyBiochemistryTranslocation Geneticimmune system diseaseshemic and lymphatic diseasesGene duplicationmedicineHumansRNA NeoplasmAgedChromosomes Human Pair 14medicine.diagnostic_testGene Expression ProfilingGene AmplificationMALT lymphomaLymphoma B-Cell Marginal ZoneCell BiologyHematologyMiddle Agedmedicine.diseaseMolecular biologyGenes bcl-2Neoplasm ProteinsGene Expression Regulation NeoplasticGene expression profilingMALT1Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinCaspasesB-Cell Non-Hodgkin LymphomaImmunoglobulin heavy chainFemaleChromosomes Human Pair 18Comparative genomic hybridizationFluorescence in situ hybridizationBlood
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

SETIL: Italian multicentric epidemiological case–control study on risk factors for childhood leukaemia, non hodgkin lymphoma and neuroblastoma: study…

2014

Background Aetiology of childhood leukaemia and childhood neoplasm is poorly understood. Information on the prevalence of risk factors in the childhood population is limited. SETIL is a population based case–control study on childhood leukaemia, conducted with two companion studies on non-Hodgkin Lymphoma (NHL) and neuroblastoma. The study relies on questionnaire interviews and 50 Hz magnetic field (ELF-MF) indoor measurements. This paper discusses the SETIL study design and includes descriptive information. Methods The study was carried out in 14 Italian regions (78.3% of Italian population aged 0–10). It included leukaemia, NHL and neuroblastoma cases incident in 0–10 year olds in 1998–20…

MalePediatricsPassive smokingLymphomaEpidemiologyNon hogdkin lymphomamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataNeuroblastomaEconomicahemic and lymphatic diseasesEpidemiologyPrevalencerisk factorsLeukaemiaChildeducation.field_of_studyIncidence (epidemiology)IncidenceLymphoma Non-Hodgkinnon hodgkin lymphoma and neuroblastomaEnvironmental exposureItalyChild PreschoolPopulation studyFemaleHumanmedicine.medical_specialtyPopulationNon-HodgkinSocio-culturalestudy populationRisk Assessmentchildhood leukaemiamedicineHumanseducationPreschoolPregnancybusiness.industryResearchrisk factors; childhood leukaemia; non hodgkin lymphoma and neuroblastoma; study populationCase-control studyInfant NewbornAmbientaleInfantEnvironmental Exposuremedicine.diseaseNewbornbusiness
researchProduct

Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD

2017

Abstract Purpose To evaluate whether imaging features of pathologic lymph nodes on whole-body diffusion-weighted MR have a predictive role before treatment and may assess the response after two courses of chemotherapy in comparison to FDG-PET/CT in Hodgkin Lymphoma. Materials and methods We reviewed the whole-body MR and FDG-PET/CT performed on 41 patients with Hodgkin Lymphoma before and after two Doxorubicin-Bleomycin-Vinblastine-Dacarbazine (ABVD). Responder and non-responder lesions were identified on interim-FDG-PET/CT performed after two ABVD. We used Multivariate Generalized Estimating Equations model to assess statistical association between being-responder and baseline-Maximum Stan…

MalePredictive Value of Test030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsWhole Body ImagingStage (cooking)medicine.diagnostic_testGeneral MedicineMiddle AgedHodgkin DiseaseDacarbazinePositron emission tomography030220 oncology & carcinogenesisPredictive value of testsRadiopharmaceuticalFemaleRadiologyHumanmedicine.drugAdultPositron emission tomographymedicine.medical_specialtyAdolescentDacarbazineWhole body imagingStandardized uptake valueVinblastineBleomycinYoung Adult03 medical and health sciencesMagnetic resonance imagingPredictive Value of TestsFluorodeoxyglucose F18medicineHumansRadiology Nuclear Medicine and imagingAgedAntineoplastic Combined Chemotherapy ProtocolHodgkin Lymphomabusiness.industryABVDDiffusion weighted imagingMagnetic resonance imagingDiffusion Magnetic Resonance ImagingABVDDoxorubicinRadiopharmaceuticalsbusinessEuropean Journal of Radiology
researchProduct